


OTC Artificial Tears Market Expected to Rise at 5.20% CAGR during 2022-2027

IMARC Group expects the global OTC artificial tears market to reach US\$ 6.41 Billion by 2027, exhibiting at a CAGR of 5.20% during 2022-2027.

SHERIDAN, WYOMING, UNITED STATES, February 1, 2022 /EINPresswire.com/ --Over Counter (OTC) artificial tears are lubricant eye drops that are primarily used for treating dryness and providing relief from pain in the eyes.



Manufactured using carboxymethyl

cellulose, polyvinyl alcohol, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and hyaluronic acid, their usage helps in treating various eye disorders, such as infections and allergies. These eye drops are widely available in the market in the form of ointment, spray, emulsion, solution, and gel.

OTC Artificial Tears Industry Trends and Drivers:

The global market is primarily driven by the increasing incidences of dry eye syndrome. Furthermore, the widespread adoption of advanced technologies by key market players to develop artificial tears, including small molecule, biologic and recombinant, is significantly contributing to the market growth across the globe.

Moreover, rising investments in research and development (R&D) activities to develop effective product variants have created a positive outlook for the market. Additionally, the growing geriatric population that is more prone to developing eye disorders, increasing healthcare expenditure and continual improvements in e-pharmacy solutions are also providing an impetus to market growth.

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: <u>https://bit.ly/32tVowk</u>

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the

indirect influence of associated industries. These observations will be integrated into the report.

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

AbbVie Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Johnson & Johnson, Nicox S.A., OASIS Medical, OCuSOFT Inc., Santen Pharmaceutical Co. Ltd., Similasan Corporation, Sun Pharmaceutical Industries Ltd. and URSAPHARM Arzneimittel GmbH.

The report has segmented the market on the basis of region, product, container type, formulation, application and distribution channel.

Breakup by Product:

Solution Ointment Emulsion Gel Spray Solution Suspensions

Breakup by Container Type:

Plastic Single Dose Container Plastic Multi-Dose Container Others

Breakup by Formulation:

Preservative Based Non-Preservative Based

Breakup by Application:

Dry Eye Syndrome Allergies Infections UV and Blue Light Protection Contact Lens Moisture Retention Others

Breakup by Distribution Channel:

Hospital Pharmacies Drug Store and Retail Pharmacies Online Pharmacies

Breakup by Region:

North America: (United States, Canada) Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others) Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others) Latin America: (Brazil, Mexico, Others) Middle East and Africa

Get a PDF Sample for more detailed market insights: <u>https://www.imarcgroup.com/otc-artificial-</u> <u>tears-market/requestsample</u>

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

Market Performance (2016-2021) Market Outlook (2022- 2027) Porter's Five Forces Analysis Market Drivers and Success Factors SWOT Analysis Value Chain Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Elena Anderson IMARC Services Private Limited +1 6317911145 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/562021811

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.